Evidence map›Paper›PMID 30181359›Full record

ReviewGenes & development2018

Genetics and biology of prostate cancer.

Guocan Wang, Di Zhao, Denise J Spring, Ronald A DePinho

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes & development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 439 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
439citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

439 citing papers in PubMed, 6 syntheses or guidelines pooled it, 749 citations in OpenAlex.

  1. A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Network Pharmacology and Molecular Docking ofInternational journal of molecular sciences · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

379 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Guocan Wang *Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Di Zhao *Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Denise J SpringDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Ronald A DePinhoDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

MDSC-Tumor Crosstalk in Prostate Cancer Progression and Castration ResistanceR00CA194289 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, GUOCAN · 2018 to 2020
$702k
NCI NIH HHS R00 CA194289
6 · The paper itself

Abstract

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer remains largely incurable even after intensive multimodal therapy. The lethality of advanced disease is driven by the lack of therapeutic regimens capable of generating durable responses in the setting of extreme tumor heterogeneity on the genetic and cell biological levels. Here, we review available prostate cancer model systems, the prostate cancer genome atlas, cellular and functional heterogeneity in the tumor microenvironment, tumor-intrinsic and tumor-extrinsic mechanisms underlying therapeutic resistance, and technological advances focused on disease detection and management. These advances, along with an improved understanding of the adaptive responses to conventional cancer therapies, anti-androgen therapy, and immunotherapy, are catalyzing development of more effective therapeutic strategies for advanced disease. In particular, knowledge of the heterotypic interactions between and coevolution of cancer and host cells in the tumor microenvironment has illuminated novel therapeutic combinations with a strong potential for more durable therapeutic responses and eventual cures for advanced disease. Improved disease management will also benefit from artificial intelligence-based expert decision support systems for proper standard of care, prognostic determinant biomarkers to minimize overtreatment of localized disease, and new standards of care accelerated by next-generation adaptive clinical trials.

Indexed as

AnimalsDrug Resistance, NeoplasmGene FusionHumansMaleMiceNeoplasm MetastasisPrognosisProstateProstatic NeoplasmsTumor Microenvironmentprostate cancertherapy resistancetumor microenvironment

Identifiers

PMID30181359
PMCPMC6120714
OpenAlexW2890411695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.